Literature DB >> 3872905

Characterization of a human interleukin 1 inhibitor.

Z Liao, A Haimovitz, Y Chen, J Chan, D L Rosenstreich.   

Abstract

Human urine contains a specific inhibitor of interleukin 1 (IL 1) that is found in increased amounts during fever. This inhibitor was purified by using a sequence of ammonium sulfate fractionation, DEAE cellulose ion-exchange chromatography, molecular sieve chromatography on Sephacryl S-200, affinity chromatography on concanavalin A (Con A) Sepharose, and polyacrylamide gel electrophoresis. Two peaks of IL 1 inhibitory material were eluted from the polyacrylamide gels. One peak contained three proteins of 29, 32, and 67 kd, respectively, which could be visualized by silver staining. The second peak contained only a small amount of the 67 kd protein. A partially purified inhibitor fraction was found to cross-react with antisera directed against two low m.w. urine trypsin inhibitors that are cleavage products of the serum inter-alpha-trypsin inhibitor. Although these findings suggest that the urine IL 1 inhibitor may be related to the inter-alpha-trypsin inhibitor, a more exact identification will require either a homogeneous inhibitor preparation or a monospecific antiserum.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872905

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Occurrence of interleukin-1 in human synovial fluid: detection by RIA, bioassay and presence of bioassay-inhibiting factors.

Authors:  J B Smith; M H Bocchieri; L Sherbin-Allen; M Borofsky; J L Abruzzo
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

2.  The effect of experimental haemocarbofiltration upon activity of mononuclear cells from normal and autoimmune patients.

Authors:  S A Grando; B T Glukhenky; G N Drannik; A P Kostromin; A B Romanenko
Journal:  Immunology       Date:  1989-01       Impact factor: 7.397

3.  Modulation of gingival Langerhans cell T6 antigen expression in vitro by interleukin 1 and an interleukin 1 inhibitor.

Authors:  L J Walsh; G J Seymour; R N Powell
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

Review 4.  Roles of interferon produced in physiological conditions. A speculative review.

Authors:  V Bocci
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

5.  Impact of the Type I Interferon Receptor on the Global Gene Expression Program During the Course of Dendritic Cell Maturation Induced by Polyinosinic Polycytidylic Acid.

Authors:  Amy L Olex; William H Turkett; Kristina L Brzoza-Lewis; Jacquelyn S Fetrow; Elizabeth M Hiltbold
Journal:  J Interferon Cytokine Res       Date:  2016-04-01       Impact factor: 2.607

6.  Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1.

Authors:  S J Hopkins; M Humphreys; M I Jayson
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

7.  Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide.

Authors:  T Nishihara; T Koga; S Hamada
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

8.  Uromodulin, an immunosuppressive protein derived from pregnancy urine, is an inhibitor of interleukin 1.

Authors:  K M Brown; A V Muchmore; D L Rosenstreich
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  An interleukin-1 inhibitor in gingival crevicular fluid of patients with chronic inflammatory periodontal disease.

Authors:  H Kabashima; K Maeda; H Iribe; K Yamashita; T Hirofuji; Y Iwamoto; M Aono
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

10.  Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses.

Authors:  Philip T Liu; Mirjam Schenk; Valencia P Walker; Paul W Dempsey; Melissa Kanchanapoomi; Matthew Wheelwright; Aria Vazirnia; Xiaoran Zhang; Andreas Steinmeyer; Ulrich Zügel; Bruce W Hollis; Genhong Cheng; Robert L Modlin
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.